The TheraSure-CNI MONITOR is suitable for therapy monitoring for patients under chemotherapy or immunotherapy and for recurrence monitoring after tumor resection.
Information for patients undergoing chemotherapy or immunotherapy and for recurrence monitoring after tumor resection.
Decisive for the success of therapy is the proof of the individual effectiveness of the therapy chosen for the patient. Studies have shown for various cancers that after radio-, chemo- or immunotherapy changes in the individual so-called CNI value can assess the success of the therapy with great accuracy. The TheraSure-CNI MONITOR was developed for this purpose.
The proof of the individual effectiveness of the therapy in the patient is decisive for the success of the therapy. In studies of patients with 11 different cancers who underwent radio-, chemo- or immunotherapy, changes in individual CNI levels demonstrated that in the absence of a significant decrease or even increase in CNI levels, the tumor did not respond to the respective therapy.
A tumor may initially respond well to systemic therapy but develop resistance as therapy progresses. In a study of patients receiving conventional cytolytic anticancer therapy, we showed that patients with a good initial response showed an increase in CNI levels after three months. Such an increase in CNI level was associated with tumor recurrence in each of the cases seen.